Meridian Bioscience (VIVO) Reports In-Line Q2 EPS

Meridian Bioscience (NASDAQ: VIVO) reported Q2 EPS of $0.24, in-line with the analyst estimate of $0.24. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $52.1 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Deutsche Bank Starts Tandem Diabetes Care (TNDM) at Hold